top of page

SOCIAL IMPACT

IMPACTING THE FUTURE OF MEDICINE THROUGH FINANCING NEW THERAPEUTIC PLATFORMS

Advanced biotherapeutics are key to addressing the challenges of modern-day healthcare with spiralling costs of long-term chronic illness and lack of cures

RESPONSIBLE INVESTMENTS INTO GOOD HEALTH AND WELL-BEING

4BIO Capital is a signatory of the UN Principles for Responsible Investment, and actively implements ESG criteria in its investment practices.

In 2015, the UN adopted the Agenda for Sustainable Development, including a set of 17 Sustainable Development Goals (SDGs), of which GOOD HEALTH AND WELL-BEING IS RANKED #3

  • Uncurbable, often fatal genetic diseases in adults and children

  • Large cost on society and individuals through disability and childhood mortality

  • Most of the morbidity, quality of life pressures and healthcare spending arise from non-communicable diseases that are mainly degenerative in nature

  • Existing therapeutic platforms do not address the issue adequately and are often symptomatic

  • Save lives treating genetic disorders early in life  

  • May solve disabling diseases including cardiovascular, oncological and neurodegenerative disorders  

  • Biotherapeutics supplement or facilitate natural functions of the organism

  • Manufacturing is biological in nature and decreases the dependence on fossil fuels

DK1CvevU8AYp9R4.jpg

ADA-SCID (BUBBLE BOY DISEASE)

EXAMPLE OF 4BIO CAPITAL HIGH SOCIAL IMPACT INVESTMENTS

  • Defect of the ADA gene resulting in a deficiency in ADA enzyme levels 

  • Severe combined immunodeficiency 

  • Recurrent infections leading to death in the first year of life if untreated 

CURRENT TREATMENT OPTIONS: 

  • Survival is still the key

  • Chronic enzyme replacement therapy with pegylated ADA 

  • We invested into the best-in-class, curative therapy for the disease 

bottom of page